title: Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
abstract: Adjuvant tamoxifen treatment increases recurrence-free survival (RFS) and overall survival (OS) in early breast cancer, although in premenopausal patients the number of studies comparing tamoxifen vs no treatment are limited. We report herein the effect on RFS of adjuvant tamoxifen treatment in a multicentre trial of premenopausal patients with stage II breast cancer patients randomised between 1986 and 1991 to 2 years of tamoxifen treatment (n=276) or no treatment (n=288). The receptor status of the tumour was known for 541 (96%) of the patients included. Tamoxifen treatment significantly increased RFS in patients with hormone receptor-positive (oestrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+)) tumours (Relative Risk (RR) 0.65; 95% Confidence Interval (CI): 0.48-0.89, P=0.006), and the beneficial effect of tamoxifen was extended to patients with indicators of poor prognosis, such as young age and nodal-positivity. PR status was a significant predictor of response to tamoxifen in multivariate models with testing of interactions of hormone receptor status and adjuvant therapy.
authors.affiliation: Department of Surgery, Helsingborgs Lasarett, SE-251 85 Helsingborg, Sweden. lisa.ryden@pat.mas.lu.se
authors.forename: Lisa
authors.initials: L
authors.lastname: Rydén
authors.forename: Per-Ebbe
authors.initials: PE
authors.lastname: Jönsson
authors.forename: Gunilla
authors.initials: G
authors.lastname: Chebil
authors.forename: Monika
authors.initials: M
authors.lastname: Dufmats
authors.forename: Mårten
authors.initials: M
authors.lastname: Fernö
authors.forename: Karin
authors.initials: K
authors.lastname: Jirström
authors.forename: Ann-Christin
authors.initials: AC
authors.lastname: Källström
authors.forename: Göran
authors.initials: G
authors.lastname: Landberg
authors.forename: Olle
authors.initials: O
authors.lastname: Stål
authors.forename: Sten
authors.initials: S
authors.lastname: Thorstenson
authors.forename: Bo
authors.initials: B
authors.lastname: Nordenskjöld
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D017697:Premenopause; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013629:Tamoxifen / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen